$12.3B SALES IN 2023
12.7% COMPOUND ANNUAL NON-GAAP EPS GROWTH RATE SINCE 1995
Our Q4 Results Reflect
- Our fourth quarter results were in-line with our guidance, which reflected the estimated impact of the cybersecurity incident in October. We are pleased with our results as we also incurred higher-than-usual acquisition-related expenses and adjustments.
- Our distribution businesses recovered well in the second half of the quarter, and we achieved strong growth in our Technology and Value-Added Services businesses, and in global sales of implants and biomaterials.
- Introduced 2024 Non-GAAP Diluted EPS guidance of $5.00 to $5.16, reflecting growth of 11% to 15% compared with 2023. 2024 Adjusted EBITDA is expected to grow by over 15% vs. 2023.
- In the long-term we are well positioned to grow the business in-line with our financial goals of high-single-digit to low-double-digit operating income and earnings per share growth by continuing to execute on our BOLD+1 Strategic Plan.
At Henry Schein, Inc., our customers rely on us for an exceptional experience
Delivering differentiated solutions that make their practices more successful and improve patient outcomes. We are trusted advisors and consultants to our customers – enabling them to deliver the best quality patient care and enhance their practice management efficiency and profitability.
With more than 3,860 field sales consultants (including equipment sales specialists), approximately 1,950 telesales representatives, and more than 115 equipment sales and service centers worldwide, Henry Schein helps customers succeed by offering the products and services needed for delivering high-quality health care.
Stock Information
Security: (Common)
| Today's High | |
| Today's Low | |
| Volume |
Data Provided by Refinitiv. Minimum 15 minutes delayed.